Gain a whole new perspective on canine osteoarthritis

Presented by B. Duncan X. Lascelles, BSc, BVSc, PhD, CertVA, DSAS(ST), Dipl. ECVS/ACVS

Continuing education questionnaire

CE credit: 1

Name

Questions

1. Unlike humans, most cases of canine osteoarthritis result from developmental joint abnormalities making it a young dog's disease. *
2. If left untreated, chronic OA pain can lead to central nervous system sensitization, thereby increasing resistance to treatment. *
3. Canine OA is a young dog's disease and the majority of cases are diagnosed between: *
4. What are the benefits of implementing the COAST (Canine Osteoarthritis Staging Tool) in my practice? *
5. Timing of analgesic use is not critical. Studies have shown that early pain relief does not prevent deterioration of the musculoskeletal system. *
6. Use of effective analgesics for a prolonged period of time is contraindicated in the management of Canine OA due to an increased risk of serious adverse drug events. *
7. Grapiprant, the active ingredient in Galliprant, controls pain and inflammation by blocking: *
8. A multimodal approach to manage Canine OA in a young dog lame from elbow dysplasia could include: *
9. In the Target Animal Safety study, up to 15X the daily dose of grapiprant was given to 9 month-old puppies for 9 months, which resulted in no GI ulceration or perforation, no renal failure and no hepatotoxicity. *
10. In the clinical trial, the majority of GI signs in the Galliprant-treated dogs were classified as mild and resolved after a few days without treatment and none of the adverse events prompted removal of a dog from the study. *